Bone Biologics Corp (BBLG) stock
BBLGNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 6/30
$0.29−0.02 (-5.92%)
Close on Nov 18, 2026Market cap $986.22KP/E –Yield –
Bone Biologics r&d expenses
Research and development expenses are spending on new products and technology.
Bone Biologics's R&D Expenses for the twelve months ending Sep 30, 2026 was $950.11K, down 50.2% year over year. For fiscal 2025 it was $1.06M, down 50.2% from the year before. Over ten years it grew -11.7% a year on average. The highest annual figure on record is $10.17M in fiscal 2016.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.06M | -50.2% |
| FY2024 | Dec 31, 2024 | $2.13M | -69.2% |
| FY2023 | Dec 31, 2023 | $6.91M | +337.4% |
| FY2022 | Dec 31, 2022 | $1.58M | +1824.9% |
| FY2021 | Dec 31, 2021 | $82.04K | -75.9% |
| FY2020 | Dec 31, 2020 | $340.67K | -68.9% |
| FY2019 | Dec 31, 2019 | $1.10M | +948.1% |
| FY2018 | Dec 31, 2018 | $104.49K | -92.6% |
| FY2017 | Dec 31, 2017 | $1.42M | -86.1% |
| FY2016 | Dec 31, 2016 | $10.17M | +177.3% |
| FY2015 | Dec 31, 2015 | $3.67M | +488.0% |
| FY2014 | Dec 31, 2014 | $623.52K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $242.57K | +29.2% |
| Q2 FY2026 | Jun 30, 2026 | $308.75K | +61.1% |
| Q1 FY2026 | Mar 31, 2026 | $141.60K | -66.6% |
| Q4 FY2025 | Dec 31, 2025 | $257.20K | -76.7% |
| Q3 FY2025 | Sep 30, 2025 | $187.81K | -56.3% |
| Q2 FY2025 | Jun 30, 2025 | $191.61K | -45.3% |
| Q1 FY2025 | Mar 31, 2025 | $423.58K | +72.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.10M | +147.1% |
| Q3 FY2024 | Sep 30, 2024 | $429.75K | -72.7% |
| Q2 FY2024 | Jun 30, 2024 | $350.44K | -84.7% |
| Q1 FY2024 | Mar 31, 2024 | $245.63K | -90.5% |
| Q4 FY2023 | Dec 31, 2023 | $447.08K | +2440.2% |
| Q3 FY2023 | Sep 30, 2023 | $1.57M | +4226.5% |
| Q2 FY2023 | Jun 30, 2023 | $2.30M | +6547.5% |
| Q1 FY2023 | Mar 31, 2023 | $2.59M | – |
| Q2 FY2022 | Jun 30, 2022 | $17.60K | +773.0% |
| Q1 FY2022 | Mar 31, 2022 | $36.40K | -20.0% |
| Q4 FY2021 | Dec 31, 2021 | $34.53K | +59.2% |
| Q3 FY2021 | Sep 30, 2021 | $0 | -100.0% |
| Q2 FY2021 | Jun 30, 2021 | $2.02K | -77.6% |
| Q1 FY2021 | Mar 31, 2021 | $45.50K | -72.8% |
| Q4 FY2020 | Dec 31, 2020 | $21.69K | -68.3% |
| Q3 FY2020 | Sep 30, 2020 | $142.88K | +217.9% |
| Q2 FY2020 | Jun 30, 2020 | $9.00K | -97.8% |
| Q1 FY2020 | Mar 31, 2020 | $167.10K | -70.4% |
| Q4 FY2019 | Dec 31, 2019 | $68.34K | -88.9% |
| Q3 FY2019 | Sep 30, 2019 | $44.94K | – |
| Q2 FY2019 | Jun 30, 2019 | $417.57K | +122.7% |
| Q1 FY2019 | Mar 31, 2019 | $564.33K | +52.9% |
| Q4 FY2018 | Dec 31, 2018 | $613.71K | +77.8% |
| Q3 FY2018 | Sep 30, 2018 | -$1.07M | -554.9% |
| Q2 FY2018 | Jun 30, 2018 | $187.46K | -55.8% |
| Q1 FY2018 | Mar 31, 2018 | $369.01K | -9.3% |
| Q4 FY2017 | Dec 31, 2017 | $345.14K | -50.5% |
| Q3 FY2017 | Sep 30, 2017 | $234.26K | -90.5% |
| Q2 FY2017 | Jun 30, 2017 | $423.93K | – |
| Q1 FY2017 | Mar 31, 2017 | $406.89K | – |
| Q4 FY2016 | Dec 31, 2016 | $697.41K | – |
| Q3 FY2016 | Sep 30, 2016 | $2.47M | – |
See a number that looks wrong?